These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
115 related items for PubMed ID: 21173142
1. Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia? Marinelli M, Raponi S, Del Giudice I, De Propris MS, Nanni M, Intoppa S, Milani ML, Mauro FR, Guarini A, Foà R. Am J Clin Pathol; 2011 Jan; 135(1):173-4. PubMed ID: 21173142 [No Abstract] [Full Text] [Related]
3. A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples. Pekova S, Mazal O, Cmejla R, Hardekopf DW, Plachy R, Zejskova L, Haugvicova R, Jancuskova T, Karas M, Koza V, Smolej L, Bezdickova L, Kozak T. Leuk Res; 2011 Jul; 35(7):889-98. PubMed ID: 21232794 [Abstract] [Full Text] [Related]
4. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, Kern W, Haferlach T, Haferlach C. Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282 [Abstract] [Full Text] [Related]
5. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients. Klobusická M, Kusenda J, Babusíková O. Neoplasma; 2002 Jan; 49(6):387-93. PubMed ID: 12584586 [Abstract] [Full Text] [Related]
6. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Dijkstra MK, van Lom K, Tielemans D, Elstrodt F, Langerak AW, van 't Veer MB, Jongen-Lavrencic M. Leukemia; 2009 Mar; 23(3):625-7. PubMed ID: 18818704 [No Abstract] [Full Text] [Related]
7. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Campo E, Cymbalista F, Ghia P, Jäger U, Pospisilova S, Rosenquist R, Schuh A, Stilgenbauer S. Haematologica; 2018 Dec; 103(12):1956-1968. PubMed ID: 30442727 [Abstract] [Full Text] [Related]
8. NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation. Mikudina B, Goodall M, Adler AI. Lancet Oncol; 2017 Mar; 18(3):289-290. PubMed ID: 28130034 [No Abstract] [Full Text] [Related]
9. p53 protein expression in chronic lymphocytic leukemia. Sellmann L, Carpinteiro A, Nückel H, Scholtysik R, Siemer D, Klein-Hipass L, Kube D, Dürig J, Dührsen U, Stanelle J, Küppers R. Leuk Lymphoma; 2012 Jul; 53(7):1282-8. PubMed ID: 22220854 [Abstract] [Full Text] [Related]
10. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Fabris S, Mosca L, Todoerti K, Cutrona G, Lionetti M, Intini D, Matis S, Colombo M, Agnelli L, Gentile M, Spriano M, Callea V, Festini G, Molica S, Lambertenghi Deliliers G, Morabito F, Ferrarini M, Neri A. Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849 [Abstract] [Full Text] [Related]
14. Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing. Rawstron AC, Shingles J, de Tute R, Bennett F, Jack AS, Hillmen P. Cytometry B Clin Cytom; 2010 Sep; 78 Suppl 1():S42-6. PubMed ID: 20839337 [Abstract] [Full Text] [Related]
15. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia. Yuan YY, Zhu HY, Wu JZ, Xia Y, Liang JH, Wu W, Cao L, Wang L, Fan L, Li JY, Xu W. Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431 [Abstract] [Full Text] [Related]
16. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA. J Clin Oncol; 2006 Jan 20; 24(3):437-43. PubMed ID: 16344317 [Abstract] [Full Text] [Related]
17. Selection of new TP53 mutations by therapy in chronic lymphocytic leukemia. Trbusek M, Malcikova J, Mayer J. Leuk Res; 2011 Jul 20; 35(7):981-2. PubMed ID: 21376395 [No Abstract] [Full Text] [Related]
18. Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia. Fink SR, Smoley SA, Stockero KJ, Paternoster SF, Thorland EC, Van Dyke DL, Shanafelt TD, Zent CS, Call TG, Kay NE, Dewald GW. Cancer Genet Cytogenet; 2006 Jun 20; 167(2):177-81. PubMed ID: 16737921 [Abstract] [Full Text] [Related]
19. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Nakagawa Y, Yamaguchi S, Hasegawa M, Nemoto T, Inoue M, Suzuki K, Hirokawa K, Kitagawa M. Leuk Res; 2004 May 20; 28(5):487-94. PubMed ID: 15068902 [Abstract] [Full Text] [Related]
20. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas. Shao J, Li Y, Li H, Wu Q, Hou J, Liew C. Chin Med J (Engl); 2000 Sep 20; 113(9):817-22. PubMed ID: 11776078 [Abstract] [Full Text] [Related] Page: [Next] [New Search]